Tissue plasminogen activator synthesis by trabecular cells and its implications for fibrinolytic therapy of the eye

1989 ◽  
Vol 18 (3) ◽  
pp. 245-254 ◽  
Author(s):  
Ramesh C. Tripathi ◽  
James K. Park ◽  
Brenda J. Tripathi ◽  
Chunghsin Ts'ao
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Fibrinolytic Therapy ◽  
Tissue Plasminogen ◽  
Trabecular Cells

Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation

2002 ◽  
Vol 97 (4) ◽  
pp. 954-962 ◽  
Author(s):  
Veit Rohde ◽  
Ina Rohde ◽  
Ruth Thiex ◽  
Azize Ince ◽  
Axel Jung ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Treated Group ◽  
Fibrinolytic Therapy ◽  
Untreated Group ◽  
Hematoma Volume ◽  
Edema Formation ◽  
Content Type ◽  
Tissue Plasminogen ◽  
Fine Print

Object. Fibrinolysis therapy accomplished using tissue plasminogen activator (tPA) and aspiration is considered to be a viable alternative to microsurgery and medical therapy for the treatment of deep-seated spontaneous intracerebral hematomas (SICHs). Tissue plasminogen activator is a mediator of thrombin- and ischemia-related delayed edema. Because both thrombin release and ischemia occur after SICH, the authors planned to investigate the effect of fibrinolytic therapy on hematoma and delayed edema volume. Methods. A spherical hematoma was created in the frontal white matter of 18 pigs. In the tPA-treated group (nine pigs), a mean of 1.55 ml tPA was injected into the clot and the resulting liquefied blood was aspirated. Magnetic resonance (MR) imaging was performed on Days 0 (after surgery), 4, and 10, and the volumes of hematoma and edema were determined. In the animals not treated with tPA (untreated group; nine pigs), the volume of hematoma dropped from 1.43 ± 0.42 ml on Day 0 to 0.85 ± 0.28 ml on Day 10. In the tPA-treated group, the volume of hematoma was reduced from 1.51 ± 0.28 ml on Day 0 to 0.52 ± 0.39 ml on Day 10. In comparison with the untreated group, the reduction in hematoma volume was significantly accelerated (p = 0.02). In the untreated group, perihematomal edema increased from 0.32 ± 0.61 ml to 1.73 ± 0.73 ml on Day 4, before dropping to 1.17 ± 0.92 ml on Day 10. In the tPA-treated group, the volume of the edema increased from 0.09 ± 0.21 ml on Day 0 to 1.93 ± 0.79 ml on Day 4, and further to 3.34 ± 3.21 ml on Day 10. The increase in edema volume was significantly more pronounced in the tPA-treated group (p = 0.04). Conclusions. Despite a significantly accelerated reduction in hematoma volume, the development of delayed perifocal edema was intensified by fibrinolytic therapy, which is probably related to the function of tPA as a mediator of edema formation after thrombin release and ischemia. Further experimental and clinical investigations are required to establish the future role of fibrinolysis in the management of SICH.

Successful Fibrinolytic Therapy Using Tissue Plasminogen Activator in Acute Renal Failure due to Acute Thrombosis of Bilateral Renal Arteries

1993 ◽  
Vol 51 (3) ◽  
pp. 177-180
Author(s):  
Masayuki Takeda ◽  
Yasushi Katayama ◽  
Hitoshi Takahashi ◽  
Kazuhide Saito ◽  
Toshiki Tsutsui ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Fibrinolytic Therapy ◽  
Renal Arteries ◽  
Acute Thrombosis ◽  
Tissue Plasminogen

scholarly journals Fibrinolytic therapy in newborns with superior vena cava syndrome. Case report

Case reports ◽  
2020 ◽  
Vol 6 (2) ◽  
pp. 118-127
Author(s):  
Ángela Milena Díaz-Díaz ◽  
María Alejandra Ardila-Gutiérrez ◽  
Catalina Cáceres-Ramírez ◽  
Santiago Zuluaga-Salazar ◽  
María Fernanda Zuluaga-Amaya ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Superior Vena Cava ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Vena Cava ◽  
Fibrinolytic Therapy ◽  
Bleeding Complications ◽  
Tissue Plasminogen ◽  
Vena Cava Syndrome

Introduction: Superior vena cava syndrome is described as the obstruction of blood flow through the superior vena cava. The literature reports that the incidence of this pathology varies from 1 case in every 650 inhabitants and 1 case in every 3 100 inhabitants. Since this condition is very rare in the pediatric population, no clear figure has been reported regarding its incidence in children. The use of a central venous catheter in newborns is a risk factor for this condition, as it may cause a thrombus due to the inflammatory reaction against the device. Therefore, it is necessary to initiate anticoagulation management and remove the catheter.Case presentation: Premature male newborn, (31.4 weeks gestation), with acute respiratory distress syndrome, early neonatal sepsis, pneumonia, necrotizing enterocolitis on 2 occasions, intestinal obstruction due to adhesions and intestinal volvulus. At 90 days of age, he presented thrombosis of the superior vena cava without involvement of the jugular and subclavian vein junction in the right atrium. Anticoagulant management was started, but given his unfavorable evolution, a multidisciplinary medical board was held to assess the risks, benefits, and treatment options in this age group. It was decided to start intracavitary tissue plasminogen activator treatment associated with mechanical thrombectomy and angioplasty of the superior vena cava. Due to the difficulty of conducting clinical trials in this population and the rates of major bleeding complications obtained with thrombolytic therapies, there is very little information available on the use of tissue plasminogen activator in newborns. For this reason, alteplase is seldom considered as the therapy of choice. However, in patients with life-threatening thrombosis, such as the present case, the results obtained in adults could be extrapolated in search of a favorable outcome.Conclusions: Fibrinolytic therapy is a way to reduce the size of the thrombus, but it dramatically increases the risk of bleeding; consequently, these patients must be strictly monitored. In pediatric populations, due to the diameter of the blood vessels, thrombectomy is difficult to perform; additionally, recurrent thrombosis and the need for transfusion of blood products are frequent.

Sign in / Sign up

Export Citation Format

Share Document